Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Corrales, L."" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-8 z 8
    Tytuł:
    Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP).
    Autorzy:
    Ruiz-Patiño A; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.; Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad el Bosque, Bogotá, Colombia.
    Barrón F; Thoracic Oncology Unit, Instituto Nacional de Cancerología, México City, Mexico.
    Cardona AF; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.; Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad el Bosque, Bogotá, Colombia.; Clinical and Translational Oncology Group, Clínica del Country, Bogotá, Colombia.
    Corrales L; Medical Oncology Department, Hospital San Juan de Dios, San José, Costa Rica.; Thoracic Oncology Department, Centro de Investigación y Manejo del Cáncer - CIMCA, San José, Costa Rica.
    Mas L; Oncology Department, Instituto Nacional de Enfermedades Neoplásicas - IneN, Lima, Peru.
    Martín C; Medical Oncology Department, Thoracic Oncology Section, Instituto Fleming, Buenos Aires, Argentina.
    Zatarain-Barrón ZL; Thoracic Oncology Unit, Instituto Nacional de Cancerología, México City, Mexico.
    Recondo G; Medical Oncology Department, Center for Medical Education and Clinical Research (CEMIC), Buenos Aires, Argentina.
    Ricaurte L; Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad el Bosque, Bogotá, Colombia.
    Rojas L; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.; Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad el Bosque, Bogotá, Colombia.; Clinical and Translational Oncology Group, Clínica del Country, Bogotá, Colombia.; Clinical Oncology Department, Clínica Colsanitas, Bogotá, Colombia.
    Archila P; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.
    Rodríguez J; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.
    Sotelo C; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.
    Viola L; Thoracic Oncology Unit, Fundación Neumológica Colombiana- FNC, Bogotá, Colombia.
    Vargas C; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.; Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad el Bosque, Bogotá, Colombia.; Clinical and Translational Oncology Group, Clínica del Country, Bogotá, Colombia.
    Carranza H; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.; Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad el Bosque, Bogotá, Colombia.; Clinical and Translational Oncology Group, Clínica del Country, Bogotá, Colombia.
    Otero J; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.; Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad el Bosque, Bogotá, Colombia.
    Pino LE; Oncology Department, Institute of Oncology - ICAL, Fundación Santa Fe de Bogotá, Bogotá, Colombia.
    Rolfo C; Thoracic Oncology Unit, Marlene and Stewart Comprehensive Cancer Center, University of Maryland, Baltimore, Maryland, USA.
    Rosell R; Institut d'Investigació en Ciències Germans Trias i Pujol, Badalona, Spain.; Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain.
    Arrieta O; Thoracic Oncology Unit, Instituto Nacional de Cancerología, México City, Mexico.
    Pokaż więcej
    Corporate Authors:
    CLICaP
    Źródło:
    Thoracic cancer [Thorac Cancer] 2020 Sep; Vol. 11 (9), pp. 2552-2560. Date of Electronic Publication: 2020 Jul 24.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Anti-Bacterial Agents/*adverse effects
    Carcinoma, Non-Small-Cell Lung/*drug therapy
    Immune Checkpoint Inhibitors/*therapeutic use
    Immunotherapy/*adverse effects
    Lung Neoplasms/*drug therapy
    Carcinoma, Non-Small-Cell Lung/pathology ; Female ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Lung Neoplasms/pathology ; Male ; Retrospective Studies
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP).
    Autorzy:
    Ruiz-Patiño A; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.; Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad el Bosque, Bogotá, Colombia.
    Arrieta O; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), México City, Mexico.
    Cardona AF; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.; Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad el Bosque, Bogotá, Colombia.; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia.
    Martín C; Medical Oncology Department, Thoracic Oncology Section, Instituto Fleming, Buenos Aires, Argentina.
    Raez LE; Thoracic Oncology Program, Memorial Cancer Institute/Florida International University, Miami, Florida, USA.
    Zatarain-Barrón ZL; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), México City, Mexico.
    Barrón F; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), México City, Mexico.
    Ricaurte L; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.
    Bravo-Garzón MA; Hematology and Oncology Department, Hospital Militar Central, Bogotá, Colombia.
    Mas L; Oncology Department, Instituto Nacional de Enfermedades Neoplásicas - IneN, Lima, Peru.
    Corrales L; Medical Oncology Department, Hospital San Juan de Dios, San José, Costa Rica.
    Rojas L; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia.; Oncology Department, Clínica Colsanitas, Bogotá, Colombia.
    Lupinacci L; Thoracic Oncology Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
    Perazzo F; Section of Oncology, CEMIC Buenos Aires, Buenos Aires, Argentina.
    Bas C; Oncology Department, Hospital Alemán, Buenos Aires, Argentina.
    Carranza O; Oncology Department, Hospital Privado de la Comunidad de Mar del Plata, Mar del Plata, Argentina.
    Puparelli C; Medical Oncology Department, Thoracic Oncology Section, Instituto Fleming, Buenos Aires, Argentina.
    Rizzo M; Oncology Department, Hospital Austral de Buenos Aires, Buenos Aires, Argentina.
    Ruiz R; Hematology and Oncology Department, Hospital Militar Central, Bogotá, Colombia.
    Rolfo C; Thoracic Oncology Unit, Marlene and Stewart Comprehensive Cancer Center, University of Maryland, Baltimore, MD, USA.
    Archila P; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.
    Rodríguez J; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.
    Sotelo C; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.
    Vargas C; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.; Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad el Bosque, Bogotá, Colombia.; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia.
    Carranza H; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.; Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad el Bosque, Bogotá, Colombia.; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia.
    Otero J; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.; Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad el Bosque, Bogotá, Colombia.; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia.
    Pino LE; Oncology Department, Institute of Oncology - ICAL, Fundación Santa Fe de Bogotá, Bogotá, Colombia.
    Ortíz C; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia.
    Laguado P; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia.
    Rosell R; Coyote Research Group, Pangaea Oncology, Laboratory of Molecular Biology, Quiron-Dexeus University Institute, Barcelona, Spain.; Institut d'Investigació en Ciències Germans Trias i Pujol, Badalona, Spain.; Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain.
    Pokaż więcej
    Corporate Authors:
    CLICaP
    Źródło:
    Thoracic cancer [Thorac Cancer] 2020 Feb; Vol. 11 (2), pp. 353-361. Date of Electronic Publication: 2019 Dec 12.
    Typ publikacji:
    Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antineoplastic Agents, Immunological/*therapeutic use
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Carcinoma, Non-Small-Cell Lung/*mortality
    Carcinoma, Squamous Cell/*mortality
    Immunotherapy/*mortality
    Lung Neoplasms/*mortality
    Adult ; Aged ; Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/immunology ; Carcinoma, Non-Small-Cell Lung/pathology ; Carcinoma, Squamous Cell/drug therapy ; Carcinoma, Squamous Cell/immunology ; Carcinoma, Squamous Cell/pathology ; Female ; Follow-Up Studies ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/immunology ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Survival Rate
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Innate immune mediators in cancer: between defense and resistance.
    Autorzy:
    Berraondo P; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.
    Minute L; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.
    Ajona D; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Program of Solid Tumors and Biomarkers, CIMA, Pamplona, Spain.; Deparment of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain.
    Corrales L; Aduro Biotech, Berkeley, CA, USA.
    Melero I; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.
    Pio R; Navarra Institute for Health Research (IDISNA), Pamplona, Spain. .; Program of Solid Tumors and Biomarkers, CIMA, Pamplona, Spain. .; Deparment of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain. .
    Pokaż więcej
    Źródło:
    Immunological reviews [Immunol Rev] 2016 Nov; Vol. 274 (1), pp. 290-306.
    Typ publikacji:
    Journal Article; Review; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Immunity, Innate*
    Cancer Vaccines/*immunology
    Complement System Proteins/*metabolism
    Immunotherapy/*methods
    Killer Cells, Natural/*immunology
    Myeloid Cells/*immunology
    Neoplasms/*immunology
    Adaptive Immunity ; Animals ; Humans ; Immunotherapy/trends ; Neoplasms/therapy ; Tumor Escape ; Tumor Microenvironment
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
      Wyświetlanie 1-8 z 8

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies